Sofinnova Partners

Cure51 was featured in The Times and The Guardian this week 🙌 . We led the company's €15 million seed round in March and they have just announced the UK launch of the Rosalind clinical study. Cure51 looks at "super survivors" of cancer to discover what makes these individuals unique. If we can understand the biological mechanisms that enable them to survive, we could one day develop therapies to make cancer a disease of the past.    Link to both pieces in the comments, check them out.

Team Sofinnova lit up the streets of Paris at the annual La Course des Lumières, all in support of cancer research! 🌟 This incredible event brought people together with one powerful goal: bringing the fight against cancer forward.   We're proud to take steps—literally—toward brighter futures. 🏃♀️✨ Hope to see many of you with us next year.

Congratulations to Freya Biosciences, a Sofinnova Partners portfolio company on its $10.4 million investment from the Bill & Melinda Gates Foundation, alongside an additional $1.4 million from Export and Investment Fund of Denmark. This additional investment brings Freya’s Series A financing to close to $50 million.   Freya Biosciences is dedicated to reimagining women's health and redefine fertility for those previously deprived of options. With a focus on microbial immunotherapies, they address immune drivers underlying a range of reproductive health conditions. Henrijette Richter

We're honored to celebrate six Sofinnova Partners portfolio companies recognized during this year's LSX - partnering for Life Science eXecutives Awards.
 🏆 Seed finance of the year: DISCO Pharmaceuticals GmbH 
 🏆 Series A finance of the year: Myricx Bio 
 🏆 IPO listing of the year: Abivax 
 🏆 Private Company CEO of the year: Barbara Angehrn Pavik, Asceneuron SA 🏆 Medtech of the year: Moon Surgical 
 🏆 Public company CEO of the year: Renee Aguiar-Lucander, Calliditas Therapeutics Our team had a great evening celebrating the acheivements of the European life sciences community. Congratulations to all the winners. Maina Bhaman Ankeet Jethwa Aseem G. Cédric Moreau Henrijette Richter Anne Osdoit, Kinam Hong, M.D., MBA, CFA

Congratulations to BrightHeart, a Sofinnova Partners MD Start portfolio company on its FDA 510(k) clearance for its first artificial intelligence software, designed to transform prenatal ultrasound evaluations of the fetal heart. BrightHeart, a Paris-based medical device company, uses AI-powered software to analyze fetal heart ultrasounds, aiding clinicians in detecting congenital heart defects prenatally. 🔗 Learn more: https://lnkd.in/er_ETW7Y Cécile Dupont Redon

Cure51, a Sofinnova Partners Digital Medicine portfolio company has launched the UK arm of its Rosalind clinical study, to deepen the understanding of cancer biology and improve patient outcomes. Approved by the NHS Equipal Committee and conducted in collaboration with eight leading hospital partners, including, Cambridge University Hospitals NHS Foundation Trust this study brings new hope to cancer patients. Cure51, aims to understand the biological mechanisms responsible for exceptional cancer survivors by identifying and validating targets that can act on these interactions, leading to first in class treatments. Learn more: https://lnkd.in/e3EPks5N Simon Turner, Edward Kliphuis, Javier Nunez-Vicandi, Aishwarya Parthasarathy

Congratulations to ELICIT PLANT a Sofinnova Partners portfolio company, on its €45m Series B fundraising round. The funding will enable the acceleration of commercial development in key regions, support strategic partnerships with major agrochemical players, and advance the company's R&D strategy. Elicit Plant is an AgTech company focused on addressing the challenges of climate change’s impact on large crops globally by reducing plants' water consumption by 20% and strengthening plant health in face of environmental stresses. Learn more: https://lnkd.in/e6djUh-h Michael Krel, Joško Bobanović, Mary McCarthy, Guillaume Baxter, Mariam Cherifi, Anna Belousova, Gabriela Sachet Fernández, PhD

Congratulations to Moon Surgical, a Sofinnova Partners portfolio company, on winning the 21st Annual Pantheon Awards in the Convergent Technologies – MedTech, Digital, & Diagnostic category. For over two decades, the California Life Sciences (CLS) awards have recognized leaders in pharmaceuticals, biotech, and allied industries for their exceptional contributions to life sciences. The Pantheon Awards celebrate excellence and honor innovators in therapeutics, diagnostics, medical devices, and industrial biotechnology.

Worth a read: According to Sifted data, biotech was Europe’s ninth most funded sector in 2024, the top industry by deal count, and highly regarded by Europe’s leading investors. Sofinnova Partners portfolio companies Bioptimus and DISCO Pharmaceuticals GmbH were 2 of the 4 rising stars. AAVantgarde Bio, BioCorteX and Cure51, also Sofinnova companies, were highlighted as early-stage startups to watch.   🔗 Go deeper on market and deal trends, key facts including a country leader board, and success stories. https://lnkd.in/e4ykBkCV

Three of our Partners, Anta Gkelou, Karl Nägler, and Matthieu Coutet spoke at this year’s #BioEurope conference, which focused on collaborative innovation. This is one of Europe’s largest biopharma events, which draws industry professionals for discussions on the current state and future direction of the industry. Anta Gkelou joined two panels and shared insights on navigating the mutual mentorship between CEOs and investors and provided valuable advice for biotechs on overcoming clinical development challenges in 2024’s complex landscape. Karl Nägler talked about strategies to strengthen the European venture landscape, highlighting the importance of clear goals, a solid plan, resources, and funding to drive the next generation of life science breakthroughs. Matthieu Coutet emphasized the importance of prioritizing Chemistry, Manufacturing, and Controls (CMC) development for pre-clinical biotech companies while pursuing clinical milestones. He noted that excellence in CMC can unlock significant value for early-stage biopharma companies. Thank you to the conference organizers for providing a valuable platform for knowledge sharing, networking, and advancing discussions on the future of biotech.